Loading
A phase 1/2 trial of Antibody-drug conjugate (ADC) in sarcomas, run by Adcendo ApS, now recruiting.
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma is a phase 1/2 interventional study registered as NCT06797999 by Adcendo ApS, with 270 participants planned, started 2025-06-05 and due to reach its primary completion in 2029-02-27. Interventions recorded: Antibody-drug conjugate (ADC).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Topoisomerase I (TOP1) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/